Associate Chief Physician, Department of Thoracic Oncology II, Peking University Cancer Hospital, Doctor of Clinical Medicine, Peking University.
Specialties: Focuses on the medical treatment of common and rare types of lung cancer, malignant pleural mesothelioma, thymic carcinoma and other thoracic tumors. Specializes in comprehensive diagnosis and treatment including tumor targeted therapy, immunotherapy and novel‑drug therapy. Has participated in or led multiple domestic and international clinical trials as well as translational research of new anti‑tumor drugs.
Academic Publications: Co‑authored Comprehensive Therapeutics for Elderly Lung Cancer. Presided over research projects funded by the Wu Jieping Medical Foundation and Beijing Cancer Prevention and Treatment Research Association. Has published numerous papers, including:
Prognostic factor analysis of patients with small cell lung cancer: Real‑world data from 988 patients. Thoracic Cancer. 2021 Jun;12(12).
Clinical outcomes of atezolizumab in combination with etoposide/platinum for treatment of extensive‑stage small‑cell lung cancer: A real‑world, multicenter, retrospective, controlled study in China. Chinese Journal of Cancer Research. 2022 Aug 30;34(4).
English